Psychiatric Genomics to Close $25M Series B Round Before New Year | GenomeWeb

WASHINGTON, DC, Oct. 3 – Psychiatric Genomics anticipates closing a Series B round of financing worth between $20 million and $25 million later in the current quarter, the company’s president and CSO told GenomeWeb on Wednesday. 

Michael Palfreyman, who is also Psychiatric Genomics’ founder, could not say what fund will be leading the round, but said that Oxford Bioscience, which led the company’s Series A round, will be a participant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.